In this context, dupilumab, targeting the IL‐4Rα‐chain and thereby the actions of IL‐4 and IL‐13, has recently been approved by the FDA for the treatment of moderate‐to‐severe AD patients (reviewed in80) and is proving to be efficacious.81, 82 Interestingly, in the context of this study, in patients undergoing dupilumab treatment IL‐1β was shown to be considerably downregulated,83 while markers of skin integrity, including FLG, are restored.84 This evidence concerns the gene IL1B and Alzheimer disease.